Neurokinin‐1 receptor: functional significance in the immune system in reference to selected infections and inflammation
暂无分享,去创建一个
[1] A. Lackner,et al. Neurokinin-1 receptor (NK1-R) expression in the brains of SIV-infected rhesus macaques: implications for substance P in NK1-R immune cell trafficking into the CNS. , 2010, The American journal of pathology.
[2] J. Weinstock,et al. TGF-β regulates T-cell neurokinin-1 receptor internalization and function , 2010, Proceedings of the National Academy of Sciences.
[3] D. Tweardy,et al. Substance P Signaling Contributes to Granuloma Formation in Taenia crassiceps Infection, a Murine Model of Cysticercosis , 2010, Journal of biomedicine & biotechnology.
[4] G. Cottrell,et al. Endosomes: A legitimate platform for the signaling train , 2009, Proceedings of the National Academy of Sciences.
[5] S. Douglas,et al. Neurokinin 1 receptor isoforms and the control of innate immunity. , 2009, Trends in immunology.
[6] D. Tweardy,et al. Substance P is required for the pathogenesis of EMCV infection in mice. , 2009, International journal of clinical and experimental medicine.
[7] Kendal G Cooper,et al. Histoplasma capsulatum Encodes a Dipeptidyl Peptidase Active against the Mammalian Immunoregulatory Peptide, Substance P , 2009, PloS one.
[8] S. Douglas,et al. Substance P (SP) enhances CCL5‐induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin‐1 receptor (NK1R) , 2008, Journal of leukocyte biology.
[9] Peter Delves,et al. Encyclopedia of life sciences , 2009 .
[10] S. Douglas,et al. Neurokinin‐1 Receptor Expression and Function in Human Macrophages and Brain , 2008, Annals of the New York Academy of Sciences.
[11] D. Tweardy,et al. Substance P Receptor Antagonism for Treatment of Cryptosporidiosis in Immunosuppressed Mice , 2008, The Journal of parasitology.
[12] Neurokinin-1 receptor mRNA expression differences in brains of HIV-infected individuals , 2008, Journal of the Neurological Sciences.
[13] S. Leeman,et al. Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor , 2008, Proceedings of the National Academy of Sciences.
[14] Xu Wang,et al. Neurokinin-1 Receptor Antagonist (Aprepitant) Suppresses HIV-1 Infection of Microglia/Macrophages , 2008, Journal of Neuroimmune Pharmacology.
[15] K. Bost,et al. Neurogenic Exacerbation of Microglial and Astrocyte Responses to Neisseria meningitidis and Borrelia burgdorferi1 , 2008, The Journal of Immunology.
[16] K. Lynch,et al. Elevated substance P levels in HIV-infected women in comparison to HIV-negative women. , 2008, AIDS research and human retroviruses.
[17] A. Cnaan,et al. Detection of full-length and truncated neurokinin-1 receptor mRNA expression in human brain regions , 2008, Journal of Neuroscience Methods.
[18] A. Goodman. Neurobiology of addiction. An integrative review. , 2008, Biochemical pharmacology.
[19] R. Di Fabio,et al. Neurokinin 1 receptor antagonists--current prospects. , 2007, Current opinion in drug discovery & development.
[20] C. Pothoulakis,et al. Functional consequences of alteration of N-linked glycosylation sites on the neurokinin 1 receptor , 2007, Proceedings of the National Academy of Sciences.
[21] P. Tebas,et al. Neurokinin-1 Receptor Antagonist (Aprepitant) Inhibits Drug-Resistant HIV-1 Infection of Macrophages in vitro , 2007, Journal of Neuroimmune Pharmacology.
[22] E. Reinke,et al. Substance P receptor mediated maintenance of chronic inflammation in EAE , 2006, Journal of Neuroimmunology.
[23] N. Page. Characterization of the gene structures, precursor processing and pharmacology of the endokinin peptides. , 2006, Vascular pharmacology.
[24] H. Satake,et al. Overview of the primary structure, tissue-distribution, and functions of tachykinins and their receptors. , 2006, Current drug targets.
[25] C. Palma. Tachykinins and their receptors in human malignancies. , 2006, Current drug targets.
[26] N. Singewald,et al. The role of substance P in stress and anxiety responses , 2006, Amino Acids.
[27] W. Ho,et al. Full-length and truncated neurokinin-1 receptor expression and function during monocyte/macrophage differentiation , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[28] W. Ho,et al. Substance P and neurokinin-1 receptor modulation of HIV , 2004, Journal of Neuroimmunology.
[29] F. Shanahan,et al. The role of substance P in inflammatory disease , 2004, Journal of cellular physiology.
[30] K. Bost,et al. Expression of hemokinin 1 mRNA by murine dendritic cells , 2004, Journal of Neuroimmunology.
[31] K. Bost,et al. Non-neuronal mammalian tachykinin expression. , 2004, Frontiers in bioscience : a journal and virtual library.
[32] D. Pascual. The role of tachykinins on bacterial infections. , 2004, Frontiers in bioscience : a journal and virtual library.
[33] K. Bost. Tachykinin-mediated modulation of the immune response. , 2004, Frontiers in bioscience : a journal and virtual library.
[34] K. Bost. Tachykinin-modulated anti-viral responses. , 2004, Frontiers in bioscience : a journal and virtual library.
[35] P. Nieto,et al. Tachykinins and tachykinin receptors: structure and activity relationships. , 2004, Current medicinal chemistry.
[36] D. Elliott,et al. Cutting Edge: Hemokinin Has Substance P-Like Function and Expression in Inflammation1 , 2004, The Journal of Immunology.
[37] Steven J. Greco,et al. Tachykinins in the emerging immune system: relevance to bone marrow homeostasis and maintenance of hematopoietic stem cells. , 2004, Frontiers in bioscience : a journal and virtual library.
[38] D. Pleasure,et al. A non‐peptide substance P antagonist (CP‐96,345) inhibits morphine‐induced NF‐κB promoter activation in human NT2‐N neurons , 2004, Journal of neuroscience research.
[39] C. Maggi,et al. Tachykinins and tachykinin receptors: a growing family. , 2004, Life sciences.
[40] S. Preskorn,et al. Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression , 2004, Neuropsychopharmacology.
[41] B. Graham,et al. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection , 2004, The Pediatric infectious disease journal.
[42] Peter Holzer,et al. Newly discovered tachykinins raise new questions about their peripheral roles and the tachykinin nomenclature. , 2004, Trends in pharmacological sciences.
[43] J. Lachowicz,et al. Identification of single-nucleotide polymorphisms of the human neurokinin 1 receptor gene and pharmacological characterization of a Y192H variant , 2004, The Pharmacogenomics Journal.
[44] K. Conzelmann,et al. Virokinin, a Bioactive Peptide of the Tachykinin Family, Is Released from the Fusion Protein of Bovine Respiratory Syncytial Virus* , 2003, Journal of Biological Chemistry.
[45] N. Rupniak. Animal models of depression: challenges from a drug development perspective. , 2003, Behavioural pharmacology.
[46] Antagonists at the neurokinin receptors--recent patent literature. , 2003, IDrugs : the investigational drugs journal.
[47] S. Hunt,et al. Clinical and neuroinflammatory responses to meningoencephalitis in substance P receptor knockout mice. , 2003, Brain : a journal of neurology.
[48] B. Adkins,et al. Immunomodulatory effects of sensory nerves during respiratory syncytial virus infection in rats. , 2003, American journal of physiology. Lung cellular and molecular physiology.
[49] Y. Hurd,et al. Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain , 2003, The European journal of neuroscience.
[50] I. Gibbins,et al. Cloning of a C-terminally truncated NK-1 receptor from guinea-pig nervous system. , 2003, Brain research. Molecular brain research.
[51] Sherine F. Elsawa,et al. Reduced CTL Response and Increased Viral Burden in Substance P Receptor-Deficient Mice Infected with Murine γ-Herpesvirus 681 , 2003, The Journal of Immunology.
[52] D. Pleasure,et al. Human neuronal cells (NT2‐N) express functional substance P and neurokinin‐1 receptor coupled to MIP‐1β expression , 2003, Journal of neuroscience research.
[53] J. Galzi,et al. Mutations in the Extracellular Amino-terminal Domain of the NK2 Neurokinin Receptor Abolish cAMP Signaling but Preserve Intracellular Calcium Responses* , 2002, The Journal of Biological Chemistry.
[54] T. Ten Have,et al. Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. , 2002, The American journal of psychiatry.
[55] Xu Wang,et al. A non-peptide substance P antagonist down-regulates SP mRNA expression in human mononuclear phagocytes , 2002, Journal of Neuroimmunology.
[56] Nadia M J Rupniak,et al. New insights into the antidepressant actions of substance P (NK1 receptor) antagonists. , 2002, Canadian journal of physiology and pharmacology.
[57] W. Ho,et al. HIV enhances substance P expression in human immune cells , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[58] Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. , 2002, Current opinion in investigational drugs.
[59] A. Cnaan,et al. Elevated substance P levels in HIV-infected men. , 2001, AIDS.
[60] J. Findlay,et al. Interaction of Met297 in the seventh transmembrane segment of the tachykinin NK2 receptor with neurokinin A. , 2001, The Journal of biological chemistry.
[61] S. Edelstein,et al. The Neurokinin A Receptor Activates Calcium and cAMP Responses through Distinct Conformational States* , 2001, The Journal of Biological Chemistry.
[62] T. Schwartz,et al. Two Active Molecular Phenotypes of the Tachykinin NK1 Receptor Revealed by G-protein Fusions and Mutagenesis* , 2001, The Journal of Biological Chemistry.
[63] C. Montell,et al. Assessment of the Role of the Inositol 1,4,5-Trisphosphate Receptor in the Activation of Transient Receptor Potential Channels and Store-operated Ca2+ Entry Channels* , 2001, The Journal of Biological Chemistry.
[64] W. Ho,et al. Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[65] K. King,et al. Exaggerated neurogenic inflammation and substance P receptor upregulation in RSV-infected weanling rats. , 2001, American journal of respiratory cell and molecular biology.
[66] W. Ho,et al. Detection of substance P and its receptor in human fetal microglia , 2000, Neuroscience.
[67] M. S. Kramer,et al. Update on Substance P (NK-1 receptor) antagonists in clinical trials for depression , 2000, Neuropeptides.
[68] N. Bunnett,et al. The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta -arrestin-dependent scaffolding complex. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[69] W. Ho,et al. Human stem cells express substance P gene and its receptor. , 2000, Journal of hematotherapy & stem cell research.
[70] F. Shanahan,et al. Differential Expression of Neurokinin-1 Receptor by Human Mucosal and Peripheral Lymphoid Cells , 2000, Clinical Diagnostic Laboratory Immunology.
[71] M S Kramer,et al. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. , 1999, Trends in pharmacological sciences.
[72] R. Raffa,et al. Substance P antagonists: the next breakthrough in treating depression? , 1999, Journal of clinical pharmacy and therapeutics.
[73] D. Elliott,et al. Immunoregulation within the granulomas of murine schistosomiasis mansoni. , 1999, Microbes and infection.
[74] R. Strieter,et al. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1α and monocyte chemotactic protein-1 , 1998, Journal of Neuroimmunology.
[75] E. Rappaport,et al. Identification of a δ isoform of preprotachykinin mRNA in human mononuclear phagocytes and lymphocytes , 1998, Journal of Neuroimmunology.
[76] S. Douglas,et al. Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis. , 1998, Blood.
[77] R G Hill,et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. , 1998, Science.
[78] W. Ho,et al. Human lymphocytes express substance P and its receptor , 1998, Journal of Neuroimmunology.
[79] C. Swain. Neurokinin receptor antagonists. , 1998, Progress in medicinal chemistry.
[80] W. Ho,et al. Human monocytes and macrophages express substance P and neurokinin-1 receptor. , 1997, Journal of immunology.
[81] G. Hauser,et al. A substance P (neurokinin-1) receptor mutant carboxyl-terminally truncated to resemble a naturally occurring receptor isoform displays enhanced responsiveness and resistance to desensitization. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[82] C. Maggi. The effects of tachykinins on inflammatory and immune cells , 1997, Regulatory Peptides.
[83] D. Perkins,et al. Severe life stress as a predictor of early disease progression in HIV infection. , 1997, The American journal of psychiatry.
[84] J. Burke,et al. A substance P antagonist, RP-67,580, ameliorates a mouse meningoencephalitic response to Trypanosoma brucei brucei. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[85] D. Payan,et al. Identification of Potential Tyrosine-containing Endocytic Motifs in the Carboxyl-tail and Seventh Transmembrane Domain of the Neurokinin 1 Receptor* , 1997, The Journal of Biological Chemistry.
[86] T. Schwartz,et al. The dual nature of the tachykinin NK1 receptor. , 1997, Trends in pharmacological sciences.
[87] P. Mantyh,et al. Differential expression of two isoforms of the neurokinin-1 (substance P) receptor in vivo , 1996, Brain Research.
[88] A. Cnaan,et al. Substance P modulates human immunodeficiency virus replication in human peripheral blood monocyte-derived macrophages. , 1996, AIDS research and human retroviruses.
[89] C. Maggi,et al. The mammalian tachykinin receptors. , 1995, General pharmacology.
[90] D. Perkins,et al. Stress-associated reductions of cytotoxic T lymphocytes and natural killer cells in asymptomatic HIV infection. , 1995, The American journal of psychiatry.
[91] D. Carney,et al. Chemotherapy induced nausea and vomiting. , 1994, Irish medical journal.
[92] J. Krause,et al. Functional nonequivalence of structurally homologous domains of neurokinin-1 and neurokinin-2 type tachykinin receptors. , 1993, The Journal of biological chemistry.
[93] S. Leeman,et al. Biochemical Characterization of Two Different Forms of the Substance P Receptor in Rat Submaxillary Gland , 1993, Journal of neurochemistry.
[94] K. B. Chou,et al. Structure, expression and second messenger-mediated regulation of the human and rat substance P receptors and their genes , 1992, Regulatory Peptides.
[95] C. Strader,et al. cDNA sequence and heterologous expression of the human neurokinin-3 receptor. , 1992, Biochemical and biophysical research communications.
[96] E. Kawashima,et al. Molecular characterisation, expression and localisation of human neurokinin‐3 receptor , 1992, FEBS letters.
[97] S. Nakanishi,et al. The primary structure and gene organization of human substance P and neuromedin K receptors. , 1992, European journal of biochemistry.
[98] K. Tsuchida,et al. Direct linkage of three tachykinin receptors to stimulation of both phosphatidylinositol hydrolysis and cyclic AMP cascades in transfected Chinese hamster ovary cells. , 1992, The Journal of biological chemistry.
[99] C. Strader,et al. Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor. , 1992, Molecular pharmacology.
[100] L. Garraway,et al. Human substance P receptor (NK-1): organization of the gene, chromosome localization, and functional expression of cDNA clones. , 1991, Biochemistry.
[101] I. Briggs,et al. Isolation and characterisation of the human lung NK-1 receptor cDNA. , 1991, Biochemical and biophysical research communications.
[102] K. B. Chou,et al. Molecular cloning, structural characterization and functional expression of the human substance P receptor. , 1991, Biochemical and biophysical research communications.
[103] A. Saltzman,et al. Cloning, Expression of the Human Substance K Receptor, and Analysis of Its Role in Mitogenesis , 1991, Annals of the New York Academy of Sciences.
[104] J. Lowe,et al. A potent nonpeptide antagonist of the substance P (NK1) receptor. , 1991, Science.
[105] R. Eddy,et al. The human neurokinin A (substance K) receptor. Molecular cloning of the gene, chromosome localization, and isolation of the cDNA from tracheal and gastric tissues. , 1990, The Journal of biological chemistry.
[106] A. Saltzman,et al. Cloning and expression of the human substance K receptor and analysis of its role in mitogenesis. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[107] S. Nakanishi,et al. Cloning and expression of a rat neuromedin K receptor cDNA. , 1990, The Journal of biological chemistry.
[108] S. Nakanishi,et al. Molecular characterization of mammalian tachykinin receptors and a possible epithelial potassium channel. , 1990, Recent progress in hormone research.
[109] S. Nakanishi,et al. Molecular characterization of a functional cDNA for rat substance P receptor. , 1989, The Journal of biological chemistry.
[110] E. Brodin,et al. Increased levels of substance P and cholecystokinin in rat cerebral cortex following repeated electroconvulsive shock and subchronic treatment with a serotonin uptake inhibitor. , 1989, Acta physiologica Scandinavica.
[111] C. Boehmer,et al. Substance P receptor binding sites are expressed by glia in vivo after neuronal injury. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[112] J. Glowinski,et al. Tachykinin Receptors of the NK1 Type (Substance P) Coupled Positively to Phospholipase C on Cortical Astrocytes from the Newborn Mouse in Primary Culture , 1989, Journal of neurochemistry.
[113] P. Mantyh,et al. Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles, venules, and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[114] E. Brodin,et al. Effects of subchronic treatment with imipramine, zimelidine and alaproclate on regional tissue levels of substance P-and neurokinin a/neurokinin B-like immunoreactivity in the brain and spinal cord of the rat , 1987, Neuropharmacology.
[115] S. Nakanishi,et al. cDNA eloping of bovine substance-K receptor through oocyte expression system , 1987, Nature.
[116] H. Hartung,et al. Substance P: binding properties and studies on cellular responses in guinea pig macrophages. , 1986, Journal of immunology.
[117] J. Nurnberger,et al. CSF substance P immunoreactivity in affective disorders , 1985, Biological Psychiatry.
[118] M. Goedert,et al. Mammalian tachykinin-induced hydrolysis of inositol phospholipids in rat brain slices. , 1985, Biochemical and biophysical research communications.
[119] Roland S. G. Jones,et al. Monoaminergic modulation of the sensitivity of neurones in the cingulate cortex to iontophoretically applied substance P , 1984, Brain Research.
[120] T. Bártfai,et al. Chronic treatment with the serotonin uptake inhibitor zimelidine elevates substance P levels in rat spinal cord. , 1984, Acta physiologica Scandinavica.
[121] N. Barden,et al. Perturbation of Rat Brain Serotonergic Systems Results in an Inverse Relation Between Substance P and Serotonin Concentrations Measured in Discrete Nuclei , 1983, Journal of neurochemistry.
[122] L. Iversen,et al. Substance P. , 1982, Journal of medicinal chemistry.
[123] V. Erspamer. The tachykinin peptide family , 1981, Trends in Neurosciences.
[124] T. Hökfelt,et al. Immunohistochemical evidence of substance P-like immunoreactivity in some 5-hydroxytryptamine-containing neurons in the rat central nervous system , 1978, Neuroscience.
[125] S L Palay,et al. Serotonin and substance P coexist i, neurons of the rat's central nervous system. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[126] M. Chang,et al. Amino-acid sequence of substance P. , 1971, Nature: New biology.
[127] M. Chang,et al. Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P. , 1970, The Journal of biological chemistry.
[128] J. Gaddum,et al. An unidentified depressor substance in certain tissue extracts , 1931, The Journal of physiology.